These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34291036)

  • 1. Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy.
    Yuan M; Chu Y; Duan Y
    Front Chem; 2021; 9():691093. PubMed ID: 34291036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs.
    Gabizon R; Shraga A; Gehrtz P; Livnah E; Shorer Y; Gurwicz N; Avram L; Unger T; Aharoni H; Albeck S; Brandis A; Shulman Z; Katz BZ; Herishanu Y; London N
    J Am Chem Soc; 2020 Jul; 142(27):11734-11742. PubMed ID: 32369353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of reversible and irreversible covalent chemistry in targeted protein degradation.
    Kiely-Collins H; Winter GE; Bernardes GJL
    Cell Chem Biol; 2021 Jul; 28(7):952-968. PubMed ID: 33789091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry.
    Guo WH; Qi X; Yu X; Liu Y; Chung CI; Bai F; Lin X; Lu D; Wang L; Chen J; Su LH; Nomie KJ; Li F; Wang MC; Shu X; Onuchic JN; Woyach JA; Wang ML; Wang J
    Nat Commun; 2020 Aug; 11(1):4268. PubMed ID: 32848159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of covalent chemistry in targeted protein degradation.
    Lu D; Yu X; Lin H; Cheng R; Monroy EY; Qi X; Wang MC; Wang J
    Chem Soc Rev; 2022 Nov; 51(22):9243-9261. PubMed ID: 36285735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.
    Yokoo H; Naganuma M; Oba M; Demizu Y
    Chem Biodivers; 2022 Nov; 19(11):e202200828. PubMed ID: 36124821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation.
    Yan J; Li T; Miao Z; Wang P; Sheng C; Zhuang C
    J Med Chem; 2022 Jul; 65(13):8798-8827. PubMed ID: 35763424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PROTACs- a game-changing technology.
    Konstantinidou M; Li J; Zhang B; Wang Z; Shaabani S; Ter Brake F; Essa K; Dömling A
    Expert Opin Drug Discov; 2019 Dec; 14(12):1255-1268. PubMed ID: 31538491
    [No Abstract]   [Full Text] [Related]  

  • 12. Small-molecule PROTACs: novel agents for cancer therapy.
    Wan Y; Yan C; Gao H; Liu T
    Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
    Chaudhry C
    J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E3 Ligase Ligands in Successful PROTACs: An Overview of Syntheses and Linker Attachment Points.
    Bricelj A; Steinebach C; Kuchta R; Gütschow M; Sosič I
    Front Chem; 2021; 9():707317. PubMed ID: 34291038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs.
    An S; Fu L
    EBioMedicine; 2018 Oct; 36():553-562. PubMed ID: 30224312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery.
    Gu S; Cui D; Chen X; Xiong X; Zhao Y
    Bioessays; 2018 Apr; 40(4):e1700247. PubMed ID: 29473971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
    Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
    Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteolysis-targeting chimeras for targeting protein for degradation.
    Qi J; Zhang G
    Future Med Chem; 2019 Apr; 11(7):723-741. PubMed ID: 30706727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for designing proteolysis targeting chimaeras (PROTACs).
    He S; Dong G; Cheng J; Wu Y; Sheng C
    Med Res Rev; 2022 May; 42(3):1280-1342. PubMed ID: 35001407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.